Medical groups sue to halt CDC vaccine advisory meeting and new child immunization guidelines under Health Secretary RFK Jr.

Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine has generated the production of antibodies, new research from the University ...

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering revenue of $678 million against estimates of $663 million and a loss of $2.

Q4 2025 earnings call highlights: revenue, cost cuts, cash outlook, FDA flu setback, and 2026 growth guidance—read key insights now.

Thank you, Kevin. Good morning, everyone, and thank you for joining us on today’s call to discuss Moderna, Inc.’s fourth quarter 2025 financial results and business update. On today’s call are ...

Moderna (NASDAQ:MRNA) executives highlighted progress on cost reductions, a ramp in international partnerships, and multiple late-stage pipeline milestones during the company’s fourth-quarter 2025 ...

Moderna reported falling fourth-quarter sales as Covid-19 vaccine demand continued to drop, but continues to target 10% revenue growth in 2026 following the launch of its next-generation Covid vaccine ...

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports ...

The Cambridge, Massachusetts-based company ​has been struggling financially as demand for ​COVID vaccines collapsed in the ⁠years ⁠following its ⁠pandemic windfall. ​It is working on newer ​products ...

Moderna said it is looking for growth overseas after the U.S. FDA refused to review its experimental flu shot and the country ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...

In an interview, Moderna President Stephen Hoge took questions on an FDA decision on the biotech's mRNA flu vaccine, as well ...